Supplemental Material to:

Lucy Liu, Marina Kritsanida, Prokopios Magiatis, Nicolas Gaboriaud, Yan Wang, Jun Wu, Ralf Buettner, Fan Yang, Sangkil Nam, Leandros Skaltsounis and Richard Jove

A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

Cancer Biology & Therapy 2012; 13(13)
http://dx.doi.org/10.4161/cbt.21781

http://www.landesbioscience.com/journals/cbt/article/21781/



Figure 1. Structures of a group of 7-bromoindirubins. Indirubin molecule was derivatized with a bromo-group at the 7-position on one indole ring, and different groups at the 3′-position on the other indole ring. MLS-2438 was selected for further study due to its potent anticancer activity.

Table S1. 7-Bromoindirubins inhibit cell viability in various cancer cell lines

MLS- / Cell lines	2420	2421	2422	2423	**2438**	2439	2442	2443	2444
A2058	104	81	107	104	**4**	77	12	75	83
DU145	84	60	87	69	**2**	37	40	57	121
LNCaP	81	8	95	66	**1**	29	5	39	42
MDA-MB-468	67	22	91	80	**5**	0	30	35	39
U87 MG	101	75	105	105	**7**	93	72	83	89
COLO205	58	18	88	69	**5**	4	8	37	15
U266	95	16	101	71	**2**	5	8	69	62
K-562	93	4	96	26	**5**	2	11	33	36
Reh	110	34	101	87	**19**	18	22	32	19
MOLT-4	86	19	82	59	**9**	7	10	9	27

NOTE: MTS cell viability assays were performed in 10 cancer cell lines including human melanoma A2058, prostate cancer DU145 and LNCaP, breast cancer MDA-MB-468, glioblastoma U87 MG, colorectal adenocarcinoma COLO 205, myeloma U266, chronic myelogenous leukemia K-562, acute lymphocytic leukemia Reh, and acute lymphoblastic leukemia MOLT-4. Cells were treated with 7-bromoindirubins at 10 μmol/L for 48 h. Cell viability was determined as percentage of the vehicle control. The cell viability values are shown as the average values of triplets, and values of the standard deviation are less than 5%.